Journal of Vascular Surgery
Volume 48, Issue 2 , Pages 377-381 , August 2008

Heparin-platelet factor 4 antibodies are frequent after vascular surgery but are not a frequent cause of graft thrombosis or thrombocytopenia

  • Tamas Alexy, MD, PhD

      Affiliations

    • Department of Physiology and Biophysics, Los Angeles County-University of Southern California (USC) Medical Center, USC University Hospital, Los Angeles, California
    • ,
  • Sonny Tucker, MD

      Affiliations

    • Department of Surgery, Los Angeles County-University of Southern California (USC) Medical Center, USC University Hospital, Los Angeles, California
    • ,
  • Soames Boyle, MS, MD

      Affiliations

    • Department of Medicine, USC-Keck School of Medicine, Los Angeles, California.
    • ,
  • Vincent L. Rowe, MD

      Affiliations

    • Department of Surgery, Los Angeles County-University of Southern California (USC) Medical Center, USC University Hospital, Los Angeles, California
    • ,
  • Fred A. Weaver, MD

      Affiliations

    • Department of Surgery, Los Angeles County-University of Southern California (USC) Medical Center, USC University Hospital, Los Angeles, California
    • ,
  • Howard A. Liebman, MA, MD

      Affiliations

    • Department of Medicine, USC-Keck School of Medicine, Los Angeles, California.
    • Corresponding Author InformationCorrespondence: Howard A. Liebman, MD, University of Southern California, 1441 Eastlake Ave, Room 3466, Los Angeles, CA 90033.

Received 27 December 2007 ,Accepted 13 March 2008.

References 

  1. Rutkow IM, Ernst CB. An analysis of vascular surgical manpower requirements in the United States. J Vasc Surg. 1997;3:74–83
  2. Whittemore AD, Donaldson MC, Mannick JA. Ten-year patency of autogenous vein bypass grafts. In:  Yao JST,  Pearce WH editor. Long-term results in vascular surgery. Norwalk, CT: Appleton & Lange; 1993;p. 243–246
  3. Bergamini TM, Towne JB, Bandyk DF, Seabrook GR, Schmitt DD. Experience with in situ saphenous vein bypasses during 1981 to 1989: determinant factors of long-term patency. J Vasc Surg. 1991;13:137–149
  4. Mills JL, Harris J, Taylor LM, Beckett WC, Porter JM. The importance of routine surveillance of distal bypass grafts with duplex scanning: a study of 379 reversed vein grafts. J Vasc Surg. 1990;12:379–389
  5. Galland RB. Inflow disease: an under-recognized cause of infra-inguinal graft failure?. Cardiovasc Surg. 2002;10:297–298
  6. Born GVR, Cross MJ. The aggregation of blood platelets. J Physiol. 1963;168:178–195
  7. Amiral J, Bridey F, Dreyfus M, Vissoc AM, Fressinaud E, Wolf M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost. 1992;68:95–96
  8. Horsewood P, Warkentin TE, Hayward CP, Kelton JG. The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol. 1996;95:161–167
  9. Warkentin TE, Chong BH, Greinacker A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost. 1998;79:1–7
  10. Reilly MP, Taylor SM, Hartman NK, Arepally GM, Sachais BS, Cinez DB, et al. Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIa. Blood. 2001;98:2442–2447
  11. Kelton JG, Smith JW, Warkentin TE, Hayward CP, Denomme GA, Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood. 1994;83:3232–3239
  12. Warkentin TE, Hayward CP, Boshkov LK, Santos AV, Sheppard JA, Bode AP, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 1994;84:3691–3699
  13. Baglin TP. Heparin induced thrombocytopenia thrombosis (HIT/T) syndrome: diagnosis and treatment. J Clin Pathol. 2001;54:272–274
  14. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344:1286–1292
  15. Cancio MLC, Cohen CDJ. Heparin-induced thrombocytopenia and thrombosis. J Am Coll Surg. 1998;186:76–91
  16. Leo A, Winteroll S. Laboratory diagnosis of heparin-induced thrombocytopenia and monitoring of alternative anticoagulants. Clin Diagn Lab Immunol. 2003;10:731–740
  17. Warkentin TE, Levine NW, Hirsh J, Horsewood P, Roberts RS, Gent M, et al. Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330–1335
  18. Kappers-Klunne MC, Boon DM, Hop WC, Michiels JJ, Stibbe J, van der Zwaan C, et al. Heparin-induced thrombocytopenia and thrombosis: a prospective analysis of the incidence in patients with heart and cerebrovascular diseases. Br J Haematol. 1997;96:442–446
  19. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med. 2001;135:502–506
  20. Rice L, Attisha WK, Drexler A, Francis JL. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med. 2002;136:210–215
  21. Jackson MR, Gillespie DL, Chang AS, Longenecker EG, Peat RA, Alving BM. The incidence of heparin-induced antibodies in patients undergoing vascular surgery: a prospective study. J Vasc Surg. 1998;28:439–445
  22. Calaitges JG, Liem TK, Spadone D, Nichols WK, Silver D. The role of heparin-associated antiplatelet antibodies in the outcome of arterial reconstruction. J Vasc Surg. 1999;29:779–786
  23. Lindhoff-Last E, Eichler P, Stein M, Plagemann J, Gerdsen F, Wagner R, et al. A prospective study on the incidence and clinical relevance of heparin-induced antibodies in patients after vascular surgery. Thromb Res. 2000;97:387–393

 Competition of interest: none.

 This study was partly supported by an unrestricted research grant from Glaxo Smith Kline and research support from Max Gondon.

PII: S0741-5214(08)00440-0

doi: 10.1016/j.jvs.2008.03.028

Journal of Vascular Surgery
Volume 48, Issue 2 , Pages 377-381 , August 2008

Article Tools